[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Transmedics Group Inc (TMDX)

Transmedics Group Inc (TMDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,899,322
  • Shares Outstanding, K 34,561
  • Annual Sales, $ 605,490 K
  • Annual Income, $ 190,290 K
  • EBIT $ 94 M
  • EBITDA $ 122 M
  • 60-Month Beta 1.90
  • Price/Sales 4.58
  • Price/Cash Flow 20.42
  • Price/Book 5.35

Options Overview Details

View History
  • Implied Volatility 56.34% (-0.85%)
  • Historical Volatility 58.18%
  • IV Percentile 24%
  • IV Rank 20.39%
  • IV High 94.20% on 10/16/25
  • IV Low 46.64% on 01/14/26
  • Expected Move (DTE 11) 7.31 (8.71%)
  • Put/Call Vol Ratio 0.19
  • Today's Volume 2,643
  • Volume Avg (30-Day) 3,266
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 59,060
  • Open Int (30-Day) 58,363
  • Expected Range 76.58 to 91.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.36
  • Number of Estimates 6
  • High Estimate $0.57
  • Low Estimate $0.15
  • Prior Year $0.66
  • Growth Rate Est. (year over year) -45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.00 +23.37%
on 08/05/26
83.98 -0.11%
on 08/07/26
+12.78 (+17.96%)
since 07/07/26
3-Month
60.10 +39.57%
on 05/13/26
83.98 -0.11%
on 08/07/26
+10.99 (+15.08%)
since 05/07/26
52-Week
60.10 +39.57%
on 05/13/26
156.00 -46.22%
on 12/02/25
-32.16 (-27.71%)
since 08/07/25

Most Recent Stories

More News
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX

NEW YORK , Aug. 5, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics...

TMDX : 83.89 (+4.59%)
TransMedics: Q2 Earnings Snapshot

TransMedics: Q2 Earnings Snapshot

TMDX : 83.89 (+4.59%)
TransMedics Reports Second Quarter 2026 Financial Results

ANDOVER, Mass. , Aug. 4, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 83.89 (+4.59%)
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). ...

TMDX : 83.89 (+4.59%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Aug. 3, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 83.89 (+4.59%)
TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference

ANDOVER, Mass. , July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 83.89 (+4.59%)
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...

TMDX : 83.89 (+4.59%)
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026

ANDOVER, Mass. , July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 83.89 (+4.59%)
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH

Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated...

TMDX : 83.89 (+4.59%)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

TMDX : 83.89 (+4.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation....

See More

Key Turning Points

3rd Resistance Point 89.88
2nd Resistance Point 86.93
1st Resistance Point 85.41
Last Price 83.89
1st Support Level 80.94
2nd Support Level 77.99
3rd Support Level 76.47

See More

52-Week High 156.00
Fibonacci 61.8% 119.37
Fibonacci 50% 108.05
Fibonacci 38.2% 96.74
Last Price 83.89
52-Week Low 60.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.